On Wednesday 27 September 2017 at London's other stock exchange, the NEX Exchange, two very different companies will be speaking to investors.
LONDON, ENGLAND, UNITED KINGDOM, September 15, 2017 /EINPresswire.com/ — On a cold wet evening in Birmingham back in November, a well-travelled CEO and Executive Chairman named Andrew Bell took centre stage at the inaugural Share Talk Investor's Evening. Andrew's company Regency Mines Plc (AIM: RGM) is listed on London's Alternative Investment Market, otherwise known as AIM. They had just set out on a journey to invest in US coal assets which they expected to turn into production by April 2017. Around 80 delegates sat and watched Andrew and his colleague Scott Kaintz as they delivered one of the slicker presentations that evening but 10 months later, investors have since been left thinking what might have been as the coal assets never lived up to the initial promise of significant income for the company. Bell insists however that good news about coal will come for investors and the shrewd sale of some of Regency's Horse Hill Development Ltd shares to UK Oil & Gas Investments (AIM: UKOG) has returned RGM a handsome profit on their initial investment having only sold around half their UKOG allocation as the oil explorer begins producing what investors hope will be positive flow test results out of their Broadford Bridge site in West Sussex.
Later this month on the 27th September in London will see Andrew Bell take the stage again as he meets investors at what is now becoming known as 'the other exchange', NEX Exchange. Andrew will be joined by Joao Andrade who is CEO of WideCells Group plc who listed on London's main FTSE market just last year. WideCells recently launched the world's first global stem cell healthcare plan, aptly named CellPlan. CellPlan has recently started rolling out in Brazil whilst the group raised £750,000 in the UK to aid progress on a number of fronts.
WideCells Group CEO, João Andrade, said, "This is an extremely exciting phase in our development as we look to accelerate the growth of all three divisions, CellPlan, WideCells and WideAcademy, through the aggressive roll out of new and existing products and services. Our growth trajectory has been steep and we are set to continue this in the coming months as our proprietary insurance product CellPlan gains traction, the marketing of INDUS, a novel synthetic bone graft which promotes new bone formation increases, and the expansion of our stem cell bank relationships as well as our own storage capabilities expands. Furthermore, having recently been granted a research licence from the UK's Human Tissue Authority, this cash injection will enable us to proceed with further cutting-edge stem cell research in a market that is projected to be worth US$170 billion by 2020 which is intended to help drive more revenues for the company in the future.
"We are ideally positioned to build on our position as a key service provider and leading international innovator in the stem cell arena. We recently ranked as the 21st most disruptive company globally by DISRUPT 100; I look forward to continuing in this vein, increasing revenue and rewarding shareholders for their support."
Both Regency Mines Plc and WideCells Group Plc will be appearing at the Share Talk Investor's Evening at the NEX Exchange, London, Wednesday 27 September 6pm. To book a place visit www.share-talk.com
Share Talk Ltd
email us here
Andrew Bell & Scott Kaintz talk to investors about Regency Mines Plc
Source: EIN Presswire